patent.fyi
Applications  /  US 2026/0355216
United States Patent Application Publication

US 2026/0355216 A1

Published
Nov 12, 2026
Filed
Aug 11, 2023
Earliest date on the face
Aug 12, 2022
Classification
A61K 31/553
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.2Methylsulfinyl group at X

What ifWhat if the carbon at X bears a methylsulfinyl group attached through sulfur?
Claim language“C1-6 alkylthio”

The substituent has the connectivity core–S(=O)–CH3. Sulfur connects the methyl group to the core, and the sulfoxide oxygen provides a hydrogen-bond acceptor.

1.3Ethynylene bridge at L1

What ifWhat if L1 connects its two attachment points through an ethynylene bridge?
Claim language“C2-5 alkenylene”

The bridge has the structure –C≡C–, with each carbon bonded to one adjoining fragment. The triple bond holds the two attachment bonds on a nearly linear axis.

1.5Saturated cage at R2

What ifWhat if R2 uses a bicyclo[1.1.1]pentan-1-yl group attached through L2?
Claim language“6- to 10-membered aryl-L2-”

L2 bonds to one bridgehead carbon of the saturated five-carbon cage. Three methylene bridges connect the two bridgeheads and constrain the cage geometry.

1.6Carbonyl bridge at L2

What ifWhat if L2 connects the two fragments through a carbonyl group?
Claim language“a single bond”

Both fragments bond to the carbonyl carbon in a fragment–C(=O)–fragment arrangement. The carbonyl carbon gives the two attachment bonds a local angle of approximately 120°, and the oxygen provides a hydrogen-bond acceptor.

1.8Oxetane ring at R2c

What ifWhat if R2c is an oxetan-3-yl group on an amide nitrogen?
Claim language“C1-6 alkyl”

The amide nitrogen bonds to the ring carbon opposite the oxygen in the four-membered oxetane ring. That carbon fixes the attachment point, and the ring oxygen provides a hydrogen-bond acceptor.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Component substitution

Sulfone in place of thioether linkage

A sulfone group replaces the thioether at Z, giving a —S(=O)₂— bridge between the same two attachment atoms. The corresponding thioether serves as the starting material, and a peracid oxidizes its sulfur through the sulfoxide to the sulfone. Liquid chromatography tracks consumption of the starting material, and high-resolution mass spectrometry checks for incorporation of two oxygen atoms.

Parameter or scale variation

Miniaturized concentration series for tumor cells

A 384-well plate holds tumor cells in 40 microliters of medium per well. The tricyclic compound is tested in triplicate at eight concentrations spaced by threefold dilutions from 10 micromolar, with the same vehicle concentration in all wells. After 72 hours, a luminescent ATP assay measures viable cell mass relative to vehicle-treated wells.

Dissolution testing across three acidity levels

Three dissolution vessels each hold 900 milliliters of medium at 37 degrees Celsius, with one vessel each at pH 1.2, 4.5, and 6.8. A paddle rotates at 50 revolutions per minute in each vessel, and each vessel receives a tablet from the same batch containing the tricyclic compound. Samples collected at 5, 15, 30, and 60 minutes are filtered and analyzed by liquid chromatography to calculate the fraction dissolved.

Combination with existing systems

Tricyclic dosing in a perfused tumor chip

A microfluidic chip holds tumor spheroids in a hydrogel chamber adjacent to a perfusion channel. A syringe pump supplies medium containing the tricyclic compound, which diffuses from the channel into the hydrogel. A second chip receives vehicle, and fluorescence imaging measures the fraction of viable cells in spheroids from both chips.

Automated or data-driven variant

Software enumeration of tricyclic compound libraries

Software stores the tricyclic framework as a molecular graph with labeled attachment atoms for L1, Z, and the side groups. It joins fragments at those atoms, checks bond orders and valences, and removes duplicate structures using canonical molecular identifiers. It computes molecular mass and polar surface area for each structure and exports the structures and descriptors in a searchable table.

Specific version of a part

Geminal fluorines on L1

L1 is a two-carbon alkylene bridge with the connectivity –CH2–CF2–. Two fluorine atoms serve as the R1 substituents on the same bridge carbon.

Methylene spaced dimethylamide

A pendant substituent on the R2 group has the structure –CH2–C(=O)–N(CH3)2. One methylene separates the attachment point from the amide carbonyl, and both substituents on the amide nitrogen are methyl groups.

Cyclopropylmethyl group at R2d

R2d is cyclopropylmethyl, with one methylene between the attachment point and a saturated three-membered carbon ring. In an amide of the form –C(=O)–NH–CH2–cyclopropyl, that methylene bonds directly to the amide nitrogen.

Trifluoromethoxy substituent on phenyl

A phenyl group bears –OCF3 para to its point of attachment to the adjoining fragment. The ether oxygen connects the phenyl ring to a single carbon bearing three fluorine atoms.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2009/0176756 A1
Published
Jul 9, 2009
Filed
Jun 26, 2008
Class
A61K 31/551
Document BUS 9,675,584 B2
Published
Jun 13, 2017
Filed
Mar 19, 2015
Class
A61K 31/404
Claim 1
Document A
Document B
1.1—N— and —CH—, the —CH— optionally substituted with Rx
1.2Rx is selected from the group consisting of deuterium, halogen, —OH, —NH2, —CN, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C1-6 alkylamino, di-C1-6 alkylamino, C1-6 haloalkyl, C1-6 haloalkoxy, C1-6 haloalkylthio, C1-6 haloalkylamino, and di-C1-6 haloalkylamino
If one or more of the substituents comprises a monocyclic or bicyclic ring system, which is mono- or polysubstituted, this may preferably be substituted with optionally 1, 2, 3, 4 or 5, particularly preferably with optionally 1, 2 or 3, substituents which may be mutually independently selected from the group consisting of F, Cl, Br, I, —CN, —NO2, —OH, —SH, —NH2, oxo (═O), thioxo (═S), —C(═O)—OH, C1-5 alkyl, —C2-5 alkenyl, —C2-5 alkynyl, —C≡C—Si(CH3)3, —C≡C—Si(C2H5)3, —(CH2)—O
A · US 2009/0176756 A1 · ¶ 35
1.3L1 is selected from the group consisting of —O—, —S—, and the following groups optionally substituted with one or more R1: —NH—, C1-5 alkylene, C1-4 heteroalkylene, C2-5 alkenylene, and C1-4 heteroalkenylene
The term “heteroalkylene” denotes an alkylene chain as described above in which one or more C atoms have in each case been replaced by a heteroatom mutually independently selected from the group consisting of oxygen, sulfur and nitrogen (NH). Heteroalkylene groups may preferably comprise 1, 2 or 3 heteroatom(s), particularly preferably one heteroatom, selected from the group consisting of oxygen, sulfur and nitrogen (NH) as chain link(s).
A · US 2009/0176756 A1 · ¶ 54
The term “alkylene,” as used herein, alone or in combination, refers to a saturated aliphatic group derived from a straight or branched chain saturated hydrocarbon attached at two or more positions, such as methylene (—CH2—).
B · US 9,675,584 B2 · ¶ 178
1.4each R1 is independently selected from the group consisting of deuterium, oxo, halogen, —OH, —NH2, —CN, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C1-6 alkylamino, di-C1-6 alkylamino, C1-6 haloalkyl, C1-6 haloalkoxy, C1-6 haloalkylthio, C1-6 haloalkylamino, and di-C1-6 haloalkylamino
Particularly preferably, alkylene, alkenylene, alkynylene, heteroalkylene or heteroalkenylene groups may be substituted with 1, 2 or 3 substituents mutually independently selected from the group consisting of phenyl, F, Cl, Br, I, —NO2, —CN, —OH, —O-phenyl, —SH, —S-phenyl, —NH2, —N(CH3)2, —N(C2H5)2 and —N(CH3)(C2H5), wherein the phenyl residue may be substituted with 1, 2, 3, 4 or 5 substituents mutually independently selected from the group consisting of F, Cl, Br, I, —OH, —
A · US 2009/0176756 A1 · ¶ 58
1.5R2 is selected from the group consisting of H, deuterium, halogen, —OH, —NH2, —CN, and the following groups optionally substituted with one or more R2: C1-12 alkyl, C1-12 heteroalkyl, 3- to 12-membered cycloalkyl-L2-, 4- to 12-membered heterocyclyl-L2-, 6- to 10-membered aryl-L2-, and 5- to 10-membered heteroaryl-L2-
R2 is chosen from cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, any of which may be optionally substituted by one or more substituents chosen from lower alkyl, lower heteroalkyl, lower heterocycloalkyl, lower haloalkyl, lower perhaloalkyl, lower perhaloalkoxy, lower cycloalkyl, aryl, aralkyl, lower alkoxy, lower haloalkoxy, carboxy, cyano, hydrogen, halogen, hydroxy, amino, lower alkylamino, amido, nitro, sulfonate, and sulfonic acid;
B · US 9,675,584 B2 · claim 1
1.6L2 is selected from the group consisting of a single bond, —O—, —S—, —NH—, —N(C1-6 alkyl)-, C1-6 alkylene, C1-6 heteroalkylene, C2-6 alkenylene, and C1-6 heteroalkenylene
The term “heteroalkylene” denotes an alkylene chain as described above in which one or more C atoms have in each case been replaced by a heteroatom mutually independently selected from the group consisting of oxygen, sulfur and nitrogen (NH). Heteroalkylene groups may preferably comprise 1, 2 or 3 heteroatom(s), particularly preferably one heteroatom, selected from the group consisting of oxygen, sulfur and nitrogen (NH) as chain link(s).
A · US 2009/0176756 A1 · ¶ 54
The term “alkylene,” as used herein, alone or in combination, refers to a saturated aliphatic group derived from a straight or branched chain saturated hydrocarbon attached at two or more positions, such as methylene (—CH2—).
B · US 9,675,584 B2 · ¶ 178
1.7each R2 is independently selected from the group consisting of deuterium, halogen, —OH, oxo, —NH2, —CN, —C(O)NR2cR2d, —NR2cC(O)R2d, —NHC(O)NR2cR2d, —NR2cC(O)OR2d, —OC(O)R2d, —C(O)OR 2, —OC(O)OR2d, —OC(O)NR2cR2d, —SO2R2d, —NHSO2R2d, —C1-6 alkylene C(O)NR2cR2d, —C1-6 alkylene NR2cC(O)R2d, —C1-6 alkylene NHC(O)NR2cR2d, —C1-6 alkylene NR2cC(O)OR2d, —C1-6 alkylene OC(O)R2d, —C1-6 alkylene C(O)OR2d, —C1-6 alkylene OC(O)NR2cR2, —C1-6 alkylene SO2R2, —C1-6 alkylene OSO2R2, —C1-6 alkylene NHSO2R2d, and the following groups optionally substituted with one or more R2b: C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, di-C1-6 alkylamino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, 3- to 12-membered cycloalkyl C1-6 alkylene, 3- to 12-membered heterocyclyl C1-6 alkylene, 6- to 10-membered aryl C1-6 alkylene, and 5- to 10-membered heteroaryl C1-6 alkylene
R2 is chosen from cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, any of which may be optionally substituted by one or more substituents chosen from lower alkyl, lower heteroalkyl, lower heterocycloalkyl, lower haloalkyl, lower perhaloalkyl, lower perhaloalkoxy, lower cycloalkyl, aryl, aralkyl, lower alkoxy, lower haloalkoxy, carboxy, cyano, hydrogen, halogen, hydroxy, amino, lower alkylamino, amido, nitro, sulfonate, and sulfonic acid;
B · US 9,675,584 B2 · claim 1
1.8R2c is independently selected from the group consisting of H, deuterium, and C1-6 alkyl
R5 and R6 are each independently chosen from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, C3-C7 heterocycloalkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl, wherein C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, C3-C7 heterocycloalkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl may be optionally substituted by one or more substituents chosen from lower alkyl, lower heteroalkyl, lower heterocycloalkyl, lower haloalkyl, lower perhalo
B · US 9,675,584 B2 · claim 1
1.9R2d is independently selected from the group consisting of H, deuterium, and the following groups optionally substituted with one or more Re: C1-6 alkyl, C1-6 heteroalkyl, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, 3- to 12-membered cycloalkyl C1-6 alkylene, 3- to 12-membered heterocyclyl C1-6 alkylene, 6- to 10-membered aryl C1-6 alkylene, and 5- to 10-membered heteroaryl C1-6 alkylene
R5 and R6 are each independently chosen from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, C3-C7 heterocycloalkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl, wherein C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, C3-C7 heterocycloalkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl may be optionally substituted by one or more substituents chosen from lower alkyl, lower heteroalkyl, lower heterocycloalkyl, lower haloalkyl, lower perhalo
B · US 9,675,584 B2 · claim 1
1.10each R2 is independently selected from the group consisting of deuterium, halogen, —OH, oxo, —NH2, —CN, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, and C1-4 haloalkoxy
If one or more of the substituents comprises a monocyclic or bicyclic ring system, which is mono- or polysubstituted, this may preferably be substituted with optionally 1, 2, 3, 4 or 5, particularly preferably with optionally 1, 2 or 3, substituents which may be mutually independently selected from the group consisting of F, Cl, Br, I, —CN, —NO2, —OH, —SH, —NH2, oxo (═O), thioxo (═S), —C(═O)—OH, C1-5 alkyl, —C2-5 alkenyl, —C2-5 alkynyl, —C≡C—Si(CH3)3, —C≡C—Si(C2H5)3, —(CH2)—O
A · US 2009/0176756 A1 · ¶ 35
R3 is chosen from hydrogen, halogen, trifluoromethyl, hydroxy, C1-C5 alkyl, and C1-C5 alkoxy, wherein C1-C5 alkyl and C1-C5 alkoxy may be optionally substituted by one or more substituents chosen from lower alkyl, lower heteroalkyl, lower heterocycloalkyl, lower haloalkyl, lower perhaloalkyl, lower perhaloalkoxy, lower cycloalkyl, aryl, aralkyl, lower alkoxy, lower haloalkoxy, carboxy, cyano, halogen, hydroxy, amino, lower alkylamino, amido, nitro, sulfonate, and sulfonic aci
B · US 9,675,584 B2 · claim 1
1.11each R2b is independently selected from the group consisting of deuterium, halogen, —OH, —NH2, —CN, C1-4 alkyl, C1-4 alkoxy, C1-4 alkylamino, di-C1-4 alkylamino, C1-4 haloalkyl, and C1-4 haloalkoxy
If one or more of the substituents comprises a monocyclic or bicyclic ring system, which is mono- or polysubstituted, this may preferably be substituted with optionally 1, 2, 3, 4 or 5, particularly preferably with optionally 1, 2 or 3, substituents which may be mutually independently selected from the group consisting of F, Cl, Br, I, —CN, —NO2, —OH, —SH, —NH2, oxo (═O), thioxo (═S), —C(═O)—OH, C1-5 alkyl, —C2-5 alkenyl, —C2-5 alkynyl, —C≡C—Si(CH3)3, —C≡C—Si(C2H5)3, —(CH2)—O
A · US 2009/0176756 A1 · ¶ 35
R3 is chosen from hydrogen, halogen, trifluoromethyl, hydroxy, C1-C5 alkyl, and C1-C5 alkoxy, wherein C1-C5 alkyl and C1-C5 alkoxy may be optionally substituted by one or more substituents chosen from lower alkyl, lower heteroalkyl, lower heterocycloalkyl, lower haloalkyl, lower perhaloalkyl, lower perhaloalkoxy, lower cycloalkyl, aryl, aralkyl, lower alkoxy, lower haloalkoxy, carboxy, cyano, halogen, hydroxy, amino, lower alkylamino, amido, nitro, sulfonate, and sulfonic aci
B · US 9,675,584 B2 · claim 1
1.12Z is selected from the group consisting of a single bond, —S—, —O—, and the following groups optionally substituted with one or more Rz: —NH— and —N(C1-12 alkyl)- each Rz is independently selected from the group consisting of deuterium, oxo, halogen, —OH, —NH2, —CN, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C1-6 alkylamino, di-C1-6 alkylamino, C1-6 haloalkyl, C1-6 haloalkoxy, C1-6 haloalkylthio, C1-6 haloalkylamino, and di-C1-6 haloalkylamino R3 is selected from the group consisting of H, deuterium, and the following groups optionally substituted with one or more R3a: C1-12 alkyl, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, 3- to 12-membered cycloalkyl C1-6 alkylene, 3- to 12-membered heterocyclyl C1-6 alkylene, 6- to 10-membered aryl C1-6 alkylene, and 5- to 10-membered heteroaryl C1-6 alkylene each R3a is independently selected from the group consisting of deuterium, halogen, —OH, oxo, —NH2, —CN, —C(O)NR3cR3d, —NR3cC(O)R3d, —NHC(O)NR3cR3d, —NR3cC(O)OR3d, —OC(O)R3d, —C(O)OR 3, —OC(O)OR3d, —OC(O)NR3cR3d, —SO2R3d, —NHSO2R3d, —C1-6 alkylene C(O)NR3cR3d, —C1-6 alkylene NR3cC(O)R3d, —C1-6 alkylene NHC(O)NR3cR3d, —C1-6 alkylene NR3cC(O)OR3d, —C1-6 alkylene OC(O)R3d, —C1-6 alkylene C(O)OR3d, —C1-6 alkylene OC(O)NR3cR3d, —C1-6 alkylene SO2R3d, —C1-6 alkylene OSO2R3d, —C1-6 alkylene NHSO2R3d, and the following groups optionally substituted with one or more R3b: ═NH, ═CH2, ═N(C1-6 alkyl), ═CH(C1-6 alkyl), ═C(C1-6 alkyl)2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, 3- to 12-membered cycloalkyl C1-6 alkylene, 3- to 12-membered heterocyclyl C1-6 alkylene, 6- to 10-membered aryl C1-6 alkylene, and 5- to 10-membered heteroaryl C1-6 alkylene R3c, is independently selected from the group consisting of H, deuterium, and C1-6 alkyl R3d is independently selected from the group consisting of H, deuterium, and the following groups optionally substituted with one or more R3e: C1-12 alkyl, C1-12 heteroalkyl, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, 3- to 12-membered cycloalkyl C1-6 alkylene, 3- to 12-membered heterocyclyl C1-6 alkylene, 6- to 10-membered aryl C1-6 alkylene, and 5- to 10-membered heteroaryl C1-6 alkylene each R3b is independently selected from the group consisting of deuterium, halogen, —OH, oxo, —NH2, —CN, C1-4 alkyl, C1-4 alkoxy, C1-4 alkylamino, and di-C1-4 alkylamino each R3e is independently selected from the group consisting of deuterium, halogen, —OH, formyl, oxo, C1-4 alkyl, and C1-4 haloalkyl R4 is selected from the group consisting of H, deuterium, halogen, —CN, C1-12 alkyl, C1-12 alkoxy, C1-12 haloalkyl, C1-12 haloalkoxy, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl ring A is selected from the group consisting of the following groups optionally substituted with one or more R5: 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl each R5 is independently selected from the group consisting of deuterium, halogen, —CN, —OH, —NH2, and the following groups optionally substituted with one or more R5a: C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C1-12 alkoxy, C1-12 alkylamino, di-C1-12 alkylamino, C1-12 alkylthio, 3- to 12-membered cycloalkyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, and 3- to 12-membered heterocyclyl each R5a is independently selected from the group consisting of deuterium, halogen, —OH, oxo, —NH2, —CN, C1-4 alkyl, C1-4 alkoxy, C1-4 alkylamino, and di-C1-4 alkylamino each L1, L2, R1, R2, R2a, R2b, R2c, R2d, R2e, R3, R3a, R3b, R3c, R3d, R3d, R4, R5, R5a, Rx, or Rz is independently optionally substituted with one or more substituents.
R2 is chosen from cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, any of which may be optionally substituted by one or more substituents chosen from lower alkyl, lower heteroalkyl, lower heterocycloalkyl, lower haloalkyl, lower perhaloalkyl, lower perhaloalkoxy, lower cycloalkyl, aryl, aralkyl, lower alkoxy, lower haloalkoxy, carboxy, cyano, hydrogen, halogen, hydroxy, amino, lower alkylamino, amido, nitro, sulfonate, and sulfonic acid;
B · US 9,675,584 B2 · claim 1

An empty cell means only that no passage was reproduced there.

Statements in these documents
There is a worldwide need for effective pain treatments.
A · US 2009/0176756 A1 · ¶ 2
Moreover, they are frequently insufficiently effective in the case of neuropathic pain, suffered in particular by tumour patients.
A · US 2009/0176756 A1 · ¶ 3
Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease.
B · US 9,675,584 B2 · ¶ 2
Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.
B · US 9,675,584 B2 · ¶ 2
Cite aspatent.fyi, US 2026/0355216 A1, claim 1, first published 2026-11-19T09:44:02-05:00, https://patent.fyi/US20260355216/, SHA-256 508c2e979a57780998c44e3daec0b60124cd21b597020e3cf71b0a4f4caad770
First published
Permanent addresshttps://patent.fyi/US20260355216/
Content fingerprint (SHA-256)508c2e979a57780998c44e3daec0b60124cd21b597020e3cf71b0a4f4caad770
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi